alogliptin

FDA Drug Profile — Nesina

alogliptin is listed in the FDA National Drug Code directory with 9 NDC codes, marketed under brand name including Nesina. Available dosage form: tablet, film coated.

Drug details

Generic Name
alogliptin
Brand Names
Nesina
Application Number
NDA022271
Sponsor
Takeda Pharmaceutical Co LTD
NDC Codes
9
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
ALOGLIPTIN BENZOATE

Indications and Usage

1 INDICATIONS AND USAGE Alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin tablet is not recommended for use in patients with type 1 diabetes mellitus.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.